Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK Biologicals' acellular pertussis vaccine · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | Subjects will receive the combined diphtheria, tetanus, acellular pertussis vaccine |
| Group B | ACTIVE_COMPARATOR | Subjects will receive the acellular pertussis vaccine and one month later the combined diphtheria and tetanus vaccine |
| Group C | ACTIVE_COMPARATOR | Subjects will receive the combined diphtheria and tetanus vaccine and one month later the acellular pertussis vaccine |
| Name | Type | Description |
|---|---|---|
| GSK Biologicals' combined diphtheria, tetanus, acellular pertussis vaccine | BIOLOGICAL | Intramuscular, single dose |
| GSK Biologicals' acellular pertussis vaccine | BIOLOGICAL | Intramuscular, single dose |
| Commonwealth Serum Laboratories' combined diphtheria and tetanus vaccine | BIOLOGICAL | Intramuscular, single dose |
Inclusion Criteria: * At least 18 years of age at the time of the vaccination * Written informed consent has been obtained Exclusion Criteria: * Evidence of confirmed pertussis disease within the previous 5 years * History of diphtheria or tetanus vaccination within the past 5 years Females must ...
GSK Biologicals' acellular pertussis vaccine is used for the prevention of diphtheria, pertussis, and tetanus in healthy adults aged 18 years and older. It is being developed as a booster vaccine to provide protection against these infectious diseases.
GSK Biologicals' acellular pertussis vaccine is developed by GSK plc, a global biopharma company listed on the stock exchange under the ticker GSK. The vaccine is currently in Phase 3 clinical development for the prevention of diphtheria, pertussis, and tetanus.
GSK Biologicals' acellular pertussis vaccine is in Phase 3 clinical development. It is an investigational vaccine and has not yet been approved by regulatory authorities. The Phase 3 trial has been completed, and the vaccine is being studied as a booster in healthy adults.
GSK Biologicals' acellular pertussis vaccine has one completed Phase 3 clinical trial registered under NCT01267058. This trial, titled "Booster Study of Combined Diphtheria-tetanus-acellular Pertussis Vaccine in Healthy Adults," enrolled 550 participants aged 18 years and older and was an active-controlled, randomized study.
GSK Biologicals' acellular pertussis vaccine is a combined vaccine that includes diphtheria, tetanus, and acellular pertussis components. It is being studied as a booster vaccine for adults to protect against all three diseases, as indicated by the clinical trial NCT01267058.